Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Anthony Boral"'
Autor:
Masami Ishii, Atsushi Horiike, Takeshi Tajima, Fumihiko Hirai, Makoto Nishio, Takashi Seto, Toshiaki Takahashi, Kota Tokushige, Matthew Robson, Haruyasu Murakami, Anthony Boral, Naoko Suenaga
Publikováno v:
Journal of Thoracic Oncology
Introduction: Anaplastic lymphoma kinase (ALK)-rearranged non–small-cell lung cancer (NSCLC) is sensitive to ALK inhibitors, but resistance develops. This study assessed the maximum-tolerated dose, safety, pharmacokinetics (PK), and antitumor activ
Autor:
Shifeng Pan, Chun Li, T Wang, Fangxian Sun, Jennifer L. Harris, Margaret E. McLaughlin, Jun Liu, Shailaja Kasibhatla, M Villarroel, X Cui, Allen G. Li, William R. Sellers, Anthony Boral, Alwin Schuller
Publikováno v:
Cancer Research. 71:PD08-11
Wnt ligands were first discovered based upon their transforming activity in the setting of mouse mammary tumor virus (MMTV) induced mammary carcinogenesis. Wnt signalling is required for normal development of the mammary gland and dysregulated Wnt si
Autor:
Suzanne George, Anthony Boral, Margaret von Mehren, Khalid Mamlouk, Patrick McNamara, Hongliang Shi, Michael Heinrich
Publikováno v:
Journal of Clinical Oncology. 36:11533-11533
11533Background: Activating mutations in KIT or PDGFRA kinases drive the vast majority of GIST in adult pts, making the disease highly amenable to targeted therapy. KIT-driven disease is more commo...
Autor:
Sagar Lonial, Hongliang Shi, S. de Vos, Amrita Krishnan, Richard I. Fisher, Brad S. Kahl, Benjamin Djulbegovic, Owen A. O'Connor, John P. Leonard, Anthony Boral, Steven H. Bernstein, Andre Goy, Sunita D. Nasta, Michael J. Robertson, Elliot M. Epner
Publikováno v:
Annals of Oncology. 20:520-525
Background We previously reported results of the phase 2, multicenter PINNACLE study, which confirmed the substantial single-agent activity of bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL). Materials and methods We rep
Autor:
Mark Chang, Anthony Boral
Publikováno v:
Pharmaceutical Medicine. 22:141-150
In the past several decades, the process of pharmaceutical development has been criticized for not being able to bring promising and safe compounds to the marketplace in a timely fashion. The use of adaptive trial designs could greatly improve the ef
Autor:
Paul G. Richardson, Joan Bladé, Morton Coleman, Laura Rosiñol, David Irwin, Jean Luc Harousseau, Michael W. Schuster, Thierry Facon, Pieter Sonneveld, Anthony Boral, Dixie Lee Esseltine, Kenneth C. Anderson, Ruben Niesvizky, Edward A. Stadtmauer, S. Vincent Rajkumar
Publikováno v:
British Journal of Haematology, 143(1), 46-53. Wiley-Blackwell Publishing Ltd
Quality of response is associated with prolonged overall survival (OS) in newly diagnosed multiple myeloma patients. This cohort study within the phase 3 Assessment of Proteasome Inhibition for Extending Remissions (APEX) trial of bortezomib versus d
Autor:
Pieter Sonneveld, Kenneth C. Anderson, Anthony Boral, Melissa Alsina, Mario Boccadoro, Hartmut Goldschmidt, Dina Ben-Yehuda, Dixie-Lee Esseltine, Jesús F. San Miguel, Andrzej Jakubowiak, Michael W. Schuster, David Irwin, Joan Bladé, Thierry Facon, Martha Q. Lacy, Jean-Luc Harousseau, Paul G. Richardson, William S. Dalton, Donna E. Reece, David P. Schenkein, Edward A. Stadtmauer, Sagar Lonial, Jamie Cavenagh, Vincent Rajkumar
Publikováno v:
Blood, 110(10), 3557-3560. American Society of Hematology
Initial analysis of the Assessment of Proteasome Inhibition for Extending Remissions (APEX) trial of relapsed multiple myeloma patients showed significantly longer time to progression, higher response rate, and improved survival with single-agent bor
Autor:
Klaus J. Busam, Ellen Neylon, David P. Schenkein, Dixie Lee Esseltine, Mithat Gonen, Anthony Boral, Julie Teruya-Feldstein, Barbara MacGregor-Cortelli, John F. Gerecitano, John J. Wright, Andre Goy, Dana L. Sachs, Owen A. O'Connor
Publikováno v:
British Journal of Haematology. 134:391-398
Summary Bortezomib is the first proteasome inhibitor to be approved for use in haematological malignancies. Although a rash has been described as a common adverse event associated with the drug, it has not been well characterised. Based on three phas
Autor:
Susan Hoare, John Radford, Elizabeth Trehu, Sandra J. Strauss, Simon P. Joel, Lynda Millard, Peter Johnson, Frances R. Balkwill, Sarah Vinnecombe, T. Andrew Lister, Ama Z. S. Rohatiner, David P. Schenkein, Anthony Boral, Lenushka Maharaj
Publikováno v:
Journal of Clinical Oncology. 24:2105-2112
Purpose To determine the efficacy of bortezomib in patients with lymphoid malignancy, correlating clinical response with effect on plasma cytokines and in vitro activity in primary cultures. Patients and Methods Patients received bortezomib (1.3 mg/m
Autor:
D. Ross Camidge, Armando Santoro, Juergen Wolf, Benjamin Solomon, Enriqueta Felip, Jeffrey A. Engelman, Daniel Shao-Weng Tan, Martin Schuler, Sunil Sharma, Johan Vansteenkiste, Alice T. Shaw, Yvonne Y. Lau, Ranee Mehra, Geoffrey Liu, Gregory J. Riely, Michael Thomas, Laura Q.M. Chow, Dong Wan Kim, Anthony Boral, Meredith Goldwasser, Tommaso De Pas
Publikováno v:
New England Journal of Medicine
BackgroundNon–small-cell lung cancer (NSCLC) harboring the anaplastic lymphoma kinase gene (ALK) rearrangement is sensitive to the ALK inhibitor crizotinib, but resistance invariably develops. Ceritinib (LDK378) is a new ALK inhibitor that has show
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ca09d7c1c5779452bb67cc2a280c916
https://europepmc.org/articles/PMC4079055/
https://europepmc.org/articles/PMC4079055/